Invention Grant
- Patent Title: Cladribine regimen for treating multiple sclerosis
-
Application No.: US15928123Application Date: 2018-03-22
-
Publication No.: US10555913B2Publication Date: 2020-02-11
- Inventor: H. James Brentzel, Jr. , Maria Lopez-Bresnahan , Nazih Ammoury
- Applicant: MERCK SERONO S.A.
- Applicant Address: CH Coinsins, Vaud
- Assignee: MERCK SERONO SA
- Current Assignee: MERCK SERONO SA
- Current Assignee Address: CH Coinsins, Vaud
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: EP06114537 20060524
- Main IPC: A61K31/00
- IPC: A61K31/00 ; A61K31/7076 ; A61P25/28 ; A61K9/20 ; A61K31/7056 ; A61K38/21
Abstract:
The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
Public/Granted literature
- US20180207109A1 CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS Public/Granted day:2018-07-26
Information query
